Patents by Inventor Edwin D. Kilbourne

Edwin D. Kilbourne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of making neuraminidase-supplemented compositions
    Patent number: 6951649
    Abstract: The present invention relates to a method for formulating a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement of the vaccine composition is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The improved composition can include and be administered with an adjuvant. The improved vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: October 4, 2005
    Assignee: Protein Sciences Corporation
    Inventors: Gail Eugene Smith, James T. Matthews, Edwin D Kilbourne, Bert E. Johansson, Bethanie E. Wilkinson, Andrie I. Voznesensky, Craig S. Hackett, Franklin Volvovitz
  • Neuraminidase-supplemented compositions
    Publication number: 20030165521
    Abstract: An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection. Oral, nasal or other mucosal or per needle administration, including intracutaneous, intradermal, intermuscular, intravascular, and intravenous injections, are included.
    Type: Application
    Filed: October 4, 2002
    Publication date: September 4, 2003
    Inventors: Gale Eugene Smith, James T. Matthews, Edwin D. Kilbourne, Bert E. Johansson, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett, Franklin Volvovitz
  • Neuraminidase-supplemented compositions
    Patent number: 6485729
    Abstract: An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be administered with an adjuvant. The vaccine composition provides protection in a host, animal or human, against influenza infection, including viral replication and systemic infection. Oral, nasal or other mucosal or per needle administration, including intracutaneous, intradermal, intramuscular, intravascular, and intravenous, are included.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: November 26, 2002
    Assignee: Protein Sciences Corporation
    Inventors: Gail Eugene Smith, James T. Matthews, Edwin D. Kilbourne, Bert E. Johansson, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett, Franklin Volvovitz
  • Influenza vaccine containing purified neuraminidase antigen and method of using the same
    Patent number: 4029763
    Abstract: An influenza vaccine is disclosed which comprises, as an active ingredient, neuraminidase antigen which has been isolated from an antigenically functional virus and has substantial cross-reactivity with the influenza virus against which the vaccine is to be effective. The neuraminidase antigen can be derived from a virus antigenically representative of the contemporary or prevalent influenza virus subtype of interest, e.g., H3N2, the Hong Kong variant of influenza.
    Type: Grant
    Filed: January 16, 1975
    Date of Patent: June 14, 1977
    Assignee: Mount Sinai School of Medicine of the City University of New York
    Inventor: Edwin D. Kilbourne
  • Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
    Patent number: 4009258
    Abstract: An influenza vaccine is disclosed which comprises, as an active ingredient, a recombinant, antigenically hydridized virus which has a hemagglutinin antigen that has substantially no cross-reactivity with those influenza viruses against which the vaccine is to be effective and a neuraminidase antigen which has substantial cross-reactivity with the influenza viruses against which the vaccine is to be effective. The neuraminidase can be derived from a virus antigenically representative of the contemporary or prevalent influenza virus of interest, e.g., H3N3, the Hong Kong variant of influenza, while the hemagglutinin antigen, in a preferred embodiment of the invention, is obtained from A-1/equine virus or from other influenza viruses of other antigenic subtypes, such as HON1 or H1N1.
    Type: Grant
    Filed: August 5, 1974
    Date of Patent: February 22, 1977
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventor: Edwin D. Kilbourne